The central figure in Nestlé's $2.6B Aimmune buyout? Covid-19

Nestlé surprised few this summer when they spent $2.6 billion to buyout Aimmune. The Swiss Butterfingers-and-health conglomerate had long shown more interest in them and Palforzia, their recently approved peanut allergy treatment, than any of the traditional Big Pharmas.